NCT07082270 2026-04-15
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Withdrawn
Clinical Trials
8 trialsNCT05773664 2024-09-19
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT03841565 2022-06-15
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT03232307 2019-08-22
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03591744 2018-12-19
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
City of Hope Medical Center
Phase 1 Withdrawn
NCT02402725 2017-02-15
UltraDex
Boston Medical Center
Phase 2 Withdrawn
NCT01329289 2016-02-12
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
University of Pittsburgh
Phase 2 Withdrawn
NCT01169415 2014-05-19
Effects of Steroid Tapering on Functional Capacity and Neurocognition
Duke University
Phase NA Withdrawn